OCULAR THERAPEUTIX, INC Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- OCULAR THERAPEUTIX, INC stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $902.00K, a 26.51% increase year-over-year.
- OCULAR THERAPEUTIX, INC stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $713.00K, a 44.92% increase year-over-year.
- OCULAR THERAPEUTIX, INC stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $492.00K, a 17.70% increase year-over-year.
- OCULAR THERAPEUTIX, INC stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $418.00K, a 13.28% decline year-over-year.
- OCULAR THERAPEUTIX, INC stock issued during period, value, employee stock purchase plan for fiscal 2025 was $1.59M, a 56.69% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC stock issued during period, value, employee stock purchase plan for fiscal 2024 was $1.02M, a 19.39% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC stock issued during period, value, employee stock purchase plan for fiscal 2023 was $851.00K, a 9.47% decline from fiscal 2022.
- OCULAR THERAPEUTIX, INC stock issued during period, value, employee stock purchase plan for fiscal 2022 was $940.00K, a 4.57% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $902.00K 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $1.59M 10-K · filed 2026-02-05 | |
| 2025-06-30 | $713.00K 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $1.02M 10-K · filed 2026-02-05 | |
| 2024-06-30 | $492.00K 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $851.00K 10-K · filed 2026-02-05 | |
| 2023-06-30 | $418.00K 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $940.00K 10-K · filed 2025-03-03 | |
| 2022-06-30 | $482.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $985.00K 10-K · filed 2024-03-11 | |
| 2021-06-30 | $490.00K 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $747.00K 10-K · filed 2023-03-06 | |
| 2020-06-30 | $350.00K 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $451.00K 10-K · filed 2022-02-28 | |
| 2019-06-30 | $294.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $297.00K 10-K · filed 2020-03-12 | |
| 2018-06-30 | $119.00K 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $276.00K 10-K · filed 2020-03-12 | |
| 2016-12-31 | $278.00K 10-K · filed 2019-03-07 | |
| 2015-12-31 | $249.00K 10-K · filed 2018-03-08 | |
| 2014-12-31 | $64.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |